Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 0.44 |
| ▸ | CXCR5 | P32302 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923182 | 1.00 | CXCR2 (1.00) | CXCR2TACR2CXCR5KDM4EALDH1A1 | |
| SCHEMBL3927234 | 1.00 | CXCR2 (1.00) | CXCR2TACR2CXCR5KDM4EALDH1A1 | |
| SCHEMBL3937535 | 0.99 | CXCR2 (0.98) | CXCR2TACR2CXCR5KDM4EALDH1A1 | |
| SCHEMBL4515861 | 0.96 | CXCR2 (0.93) | CXCR2TACR2CXCR5KDM4EALDH1A1 | |
| SCHEMBL3936452 | 0.81 | CXCR2 (0.75) | CXCR2TACR2CXCR5PYGLCYP2C9 | |
| SCHEMBL3923463 | 0.80 | CXCR2 (0.71) | CXCR2TACR2CXCR5 | |
| SCHEMBL4533691 | 0.80 | CXCR2 (0.66) | CXCR2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL4533688 | 0.80 | CXCR2 (0.66) | CXCR2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL13710827 | 0.80 | CXCR2 (0.66) | CXCR2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL4533696 | 0.80 | CXCR2 (0.66) | CXCR2KDM4EALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | claimed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | claimed |
| EP-2040688-A1 | NEW CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | claimed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| EP-2040688-A1 | NEW CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227625-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885TACR2 81/4885CXCR5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.